Activated human peripheral blood mononuclear cells
Alternative Names:
DRB1, HLA class II histocompatibility antigen, DR-1 beta chain, HLA-DR-beta 1, HLA-DRB1, human leucocyte antigen DRB1, Leucocyte antigen DR beta 1 chain, lymphocyte antigen DRB1, major histocompatibility complex, class II, DR beta 1, MHC class II HLA-DR beta 1 chain, MHC class II HLA-DR-beta cell su
This MAb reacts with a 28kDa chain of HLA-DRB1 antigen, a member of MHC class II molecules. It does not cross react with HLA-DP and HLA-DQ. The L243 antibody recognizes a different epitope than the LN3 monoclonal antibody, and these antibodies do not cross-block binding to each others respective epitopes. HLA-DR is a heterodimeric cell surface glycoprotein comprised of a 36kDa alpha (heavy) chain and a 28kDa beta (light) chain. It is expressed on B-cells, activated T-cells, monocytes/macrophages, dendritic cells and other non-professional APCs. In conjunction with the CD3/TCR complex and CD4 molecules, HLA-DR is critical for efficient peptide presentation to CD4+ T cells. It is an excellent histiocytic marker in paraffin sections producing intense staining. True histiocytic neoplasms are similarly positive. HLA-DR antigens also occur on a variety of epithelial cells and their corresponding neoplastic counterparts. Loss of HLA-DR expression is related to tumor microenvironment and predicts adverse outcome in diffuse large B-cell lymphoma.
Flow Cytometry (1-2ug/million cells), Immunofluorescence (1-2ug/ml), Western Blot (1-2ug/ml), Immunohistochemistry (Formalin-fixed) (0.25-0.5ug/ml for 30 minutes at RT)(Staining of formalin-fixed tissues requires heating tissue sections in 10mM Tris with
* VAT and and shipping costs not included. Errors and price changes excepted
